AbbVie Inc. (ABBV)
Last Price$213.6(1.4%)
Market Cap$375.8B
ABBV Rating
ABBV Quality rating performance
ABBV Intrinsic Value
Key Highlights:
As of Mar 11, 2025 ABBV Relative Value is $149.4, which is overvalued by 30.0%, compared to current share price of $213.6.
As of Mar 11, 2025 ABBV DCF Value is $454.2, which is undervalued by 112.6%, compared to current share price of $213.6.
ABBV Share Price History
1W 2.8%
1M 11.3%
6M 11.7%
YTD 39.8%
1Y 23.2%
3Y 60.4%
5Y 210.7%
10Y 471.7%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
ABBV Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$375.8B
$437.4B
$56.3B
$17.8B
Shares Outstanding
1,759M
Employees
55K
Growth (CAGR)
11.1%
(6.8%)
(14.57%)
407.82%
Profitability
73.6%
16.2%
33.4%
31.7%
418.6%
Intrinsic Value
$302.4 (41.6% undervalued)
$454.7
$150.0
$347.2
$858.1
43.6%
Return on Capital
Financial Health
$5,555.0M
$61.6B
3.5x
3.4x
1,996.0%
Dividends
12.5%
2.9%
61.8%
Apr 15, 2025
Earnings
Jul 23, 2025
BEAT by 1.8%
MISS by (38.0%)
(13.9%)
9 Beat & 1 Miss
ABBV Stock Financials
ABBV Income Statement Metrics
Annual
Quarterly
LTM
ABBV Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
$18.8B -17.7% YoY
Capital Expenditure (CAPEX)
$0.0 +25.4% YoY
Free Cash Flow (FCF)
$18.8B -19.2% YoY
ABBV Income Statement Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$56.3B 3.7% YoY
Cost of revenue
$16.9B (17.2%) YoY
Pre-tax income
$3,716.0M (40.5%) YoY
6.6% margin
ABBV Balance Sheet Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$135.2B
Current assets ($25.6B, 18.9% of total)
$5,555.0M (4.1%)
$10.9B (8.1%)
Other current assets
$9,108.0M (6.7%)
Non-current assets ($109.6B, 81.1% of total)
$279.0M (0.2%)
$5,134.0M (3.8%)
$60.1B (44.4%)
Other non-current assets
$44.1B (32.6%)
Financial position
$61.6B
Cash & Short-term
Investments
Total Debt
ABBV Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
ABBV Earnings Surprises
Crunching data... Almost there!
ABBV Dividends
ABBV Dividend Yield
Crunching data... Almost there!
ABBV Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with ABBV
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$375.8B | 6.0 | $302.4 41.6% undervalued | 23.2% | $56.3B | $17.8B | 3.7% | 31.7% | 73.6% | 8.3% | 1,996.0% | |
$743.9B | 7.0 | $225.3 72.7% overvalued | 12.9% | $45.0B | $510.8M | 32.0% | 1.1% | 81.6% | 40.7% | 235.7% | |
$398.7B | 5.9 | $197.1 18.9% undervalued | 6.2% | $88.8B | $18.1B | 4.3% | 20.3% | 69.1% | 15.7% | 51.2% | |
$346.3B | 7.1 | $72.1 7.7% overvalued | (40.0%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$240.8B | 7.5 | $112.5 18.8% undervalued | (20.7%) | $64.2B | $18.1B | 6.7% | 28.2% | 80.8% | 26.5% | 80.0% | |
$232.5B | 6.7 | $69.5 6.3% overvalued | 11.9% | $54.1B | $7,275.0M | 18.0% | 13.5% | 81.1% | 15.4% | 73.7% | |
$223.3B | 6.6 | $149.6 34.3% undervalued | 9.8% | $51.1B | $13.8B | 0.1% | 27.0% | 74.7% | 17.7% | 70.8% | |
$173.1B | 5.9 | $447.8 40.4% undervalued | 19.3% | $33.4B | $10.4B | 18.6% | 31.1% | 61.5% | 11.9% | 1,022.6% | |
$148.1B | 6.0 | $25.3 2.7% overvalued | (2.7%) | $63.6B | $9,835.0M | 8.8% | 15.5% | 65.6% | 9.0% | 71.9% | |
$146.8B | 4.7 | $91.4 55.6% undervalued | 25.2% | €44.3B | (€504.0M) | (22.5%) | (1.1%) | 70.2% | 7.4% | 23.0% | |
$143.2B | 6.1 | $91.1 20.4% overvalued | 58.1% | $28.7B | $10.5B | 6.0% | 36.4% | 78.3% | 20.1% | 138.8% |
FAQ
What is AbbVie Inc. (ABBV) stock rating?
As of today, AbbVie Inc. has a stock rating of 6 (out of 10), which is considered Good.
is AbbVie Inc. (ABBV) a good stock to buy?
As of today, AbbVie Inc. has a Good stock rating, which is 41.6% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.